Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Shares Issued (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Shares Issued for 5 consecutive years, with $29.1 million as the latest value for Q1 2025.

  • Quarterly Shares Issued changed N/A to $29.1 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $29.1 million through Dec 2025, up 12.04% year-over-year, with the annual reading at $29.1 million for FY2025, 12.04% up from the prior year.
  • Shares Issued hit $29.1 million in Q1 2025 for Insight Molecular Diagnostics, up from $10.2 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $63.7 million in Q3 2021 to a low of -$5.2 million in Q2 2021.
  • Historically, Shares Issued has averaged $13.9 million across 4 years, with a median of $6.8 million in 2021.
  • Biggest YoY gain for Shares Issued was 448.45% in 2021; the steepest drop was 147.97% in 2021.
  • Year by year, Shares Issued stood at $1000.0 in 2021, then soared by 499900.0% to $5.0 million in 2022, then soared by 104.1% to $10.2 million in 2024, then soared by 185.58% to $29.1 million in 2025.
  • Business Quant data shows Shares Issued for IMDX at $29.1 million in Q1 2025, $10.2 million in Q4 2024, and $15.8 million in Q2 2024.